Edgewise Therapeutics (EWTX) vs Travere Therapeutics (TVTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Edgewise Therapeutics (EWTX) has outperformed Travere Therapeutics (TVTX) over the past year, gaining 161.4% versus a gain of 109.6%. Over five years, EWTX leads with a +123.1% price change compared with +118.1% for TVTX. Travere Therapeutics is the larger company by market cap ($4.87 billion vs $4.15 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EWTX | TVTX |
|---|---|---|
| Share price | $38.18 | $51.69 |
| Market cap | $4.15B | $4.87B |
| 1-day change | -3.51% | -3.27% |
| YTD return | +59.46% | +39.86% |
| 1-year return | +161.36% | +109.57% |
| 5-year return | +123.06% | +118.12% |
| Forward P/E | — | 9.17 |
| EPS (TTM) | $-1.86 | $-0.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $490.73M |
| Revenue growth (YoY) | — | +110.45% |
| Net income (latest FY) | $-167.79M | $-25.55M |
| Gross margin | — | 97.89% |
| Operating margin | — | -12.80% |
| Net margin | — | -5.21% |
| 52-week high | $48.51 | $68.73 |
| 52-week low | $14.25 | $22.59 |
| Distance from 52-week high | -21.29% | -24.79% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +37.82% | +45.50% |
| Average volume | 1.35M | 1.58M |
| Shares outstanding | 108.60M | 94.26M |
| Employees | 127 | 497 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EWTX has outperformed TVTX by 51.8 percentage points over the past year.
About Edgewise Therapeutics
EWTX stock →Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
Health Care · Biotechnology: Pharmaceutical Preparations · 127 employees
About Travere Therapeutics
TVTX stock →Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Health Care · Biotechnology: Pharmaceutical Preparations · 497 employees
EWTX vs TVTX FAQ
Which is bigger, Edgewise Therapeutics or Travere Therapeutics?
Travere Therapeutics (TVTX) is larger, with a market capitalization of $4.87B compared with $4.15B for Edgewise Therapeutics (EWTX).
Which stock has performed better over the past year, EWTX or TVTX?
EWTX returned +161.36% over the past 12 months, compared with +109.57% for TVTX (price return, excluding dividends). Past performance does not predict future results.
Are Edgewise Therapeutics and Travere Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.